Raymond James Financial Services Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17,300	Closed	-$2K	–	3399
2022 Q2	$2K	Hold	17,300	–	–	﹤0.01%	3240
2022 Q1	$10K	Sell	17,300 -800	-4%	-$6.68K	﹤0.01%	3291
2021 Q4	$1K	Buy	+18,100	New	+$163K	﹤0.01%	3307
2021 Q3	–	Sell	-18,300	Closed	-$2K	–	3413
2021 Q2	$2K	Hold	18,300	–	–	﹤0.01%	3291
2021 Q1	$18K	Buy	+18,300	New	+$210K	﹤0.01%	3143
2020 Q4	–	Sell	-18,800	Closed	-$2K	–	3076
2020 Q3	$2K	Buy	+18,800	New	+$199K	﹤0.01%	2871
2020 Q1	–	Sell	-16,600	Closed	-$10K	–	2822
2019 Q4	$10K	Buy	+16,600	New	+$148K	﹤0.01%	2829

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Raymond James Financial Services Advisors's TEVA Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 7.7% in Q3 2024, selling an estimated $87.4K and leaving 59,707 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2116.

Raymond James Financial Services Advisors first reported a position in TEVA in Q2 2013 and has held it in 39 quarters since. The position peaked at $6.86M in Q1 2021. 543 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

Raymond James Financial Services Advisors held 59,707 shares of Teva Pharmaceuticals worth $1.08M as of Q3 2024.
Raymond James Financial Services Advisors sold 4,996 Teva Pharmaceuticals shares in Q3 2024, an estimated $87.4K.
Teva Pharmaceuticals made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2116 holding.
Raymond James Financial Services Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 39 quarters since.
Raymond James Financial Services Advisors's Teva Pharmaceuticals position peaked at $6.86M in Q1 2021.
543 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.